Researchers from the University of Basel and the University Hospital Basel in Switzerland have tested the possibility of artificial maturing of breast cancer cells and turning them into normal cells again.
Researchers adopted a therapeutic strategy called Differentiation, which has been successfully implemented in treating blood-borne cancers but has yet to be tried in solid tumors.
Led by Professor Mohamed Bentires-Alj, the research study provided promising results in treating an aggressive type of carcinoma called triple-negative breast cancer. Breast cancer cells are susceptible to estrogen and can be treated with anti-estrogenic therapies, which are highly effective in patients. The research team also tested more than 9,500 compounds for their efficiency in treating the cells and found kinase 1 (PLK1), an inhibitor of an essential cell cycle protein.
